Sign in
Taking people in United StatesPhase 1/2

Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning

Key facts

Who runs it
David Williams
Where
Atlanta, Boston, Cincinnati, and Los Angeles, United StatesSee the 4 sites
Trial code
Status
Recruiting
Phase
Phase 1/2
People taking part
12 people, planned
Started
26 Feb 2018
Expected to end
1 Jan 2028
Type of study
Interventional
Treatments tested
  • autologous CD34+ cell transduced with G2SCID vector
Record updated
11 December 2025

Who can take part

Age
0 years to 5 years
Sex
Men only
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • 1. Diagnosis of SCID-X1 based on immunophenotype and lack of T cell function (proliferation to PHA <10% of the lower limit of normal for the laboratory) AND confirmed by a mutation in IL2RG 2. Lack of an HLA identical (A, B, C, DR, DQ) related donor 3. Age 5 years old or younger 4. Signed informed consent 5. Documentation of willingness to follow up for 15 years post-infusion as currently required by the FDA 6. If the patient has previously undergone allogeneic transplant, lack of donor T cell engraftment must be documented
  • Age at least 8 weeks by the time of busulfan administration

Who cannot take part

  • Uncontrolled seizure disorder
  • Documented coexistence of any disorder known to affect DNA repair
  • Diagnosis of active malignant disease other than EBV-associated lymphoproliferative disease
  • Patients with evidence of infection with HIV-1
  • Major (life-threatening) congenital anomalies. Examples of "major (life-threatening) congenital anomalies" include, but are not limited to: unrepaired cyanotic heart disease, hypoplastic lungs, anencephaly or other major central nervous system malformations, other severe non-repairable malformations of the gastrointestinal or genitourinary tracts that significantly impair organ function
  • Other conditions which in the opinion of the P.I. or co-investigators, contra-indicate collection and/or infusion of transduced cells or indicate patient's inability to follow the protocol. These may include for example clinical ineligibility to receive anesthesia, severe deterioriation of clinical condition of the patient after collection of bone marrow but before infusion of transduced cells, or documented refusal or inability of the family to return for scheduled visits. There may be other unforeseen rare circumstances that would result in exclusion of the patient, such as sudden loss of legal guardianship; -
  • Patients with an active, therapy-resistant infection. Infections that are known to be highly morbid in SCID patients will be considered active and therapy-resistant if the infectious agent is repeatedly isolated despite a minimum of 2 weeks of appropriate therapy and is associated with significant organ dysfunction (including but not limited to abnormalities listed below); Mechanical ventilation including continuous positive airway pressure; Abnormal liver function defined by AST and ALT >10 times the upper range of normal OR Bilirubin >2 mg/dL; Shortening fraction on echocardiogram <25% or ejection fraction <50%; Renal failure defined as glomerular filtration rate <30 ml/min/1.73 m2 or dialysis dependence
  • Encephalopathy

The main criteria, as questions

These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Are you between 0 and 5 years old?

This trial is currently available in United States.

  • Emory University/Childrens Healthcare of AtlantaAtlanta, United StatesContact: Shanmuganathan Chandrakasan, MDTaking people
  • Boston Childrens HospitalBoston, United StatesContact: Susan Prockop, MDTaking people
  • Cincinnati Children's Hospital Medical CenterCincinnati, United StatesContact: Sharat Chandra, M.D.Taking people
  • Mattel Children's Hospital UCLALos Angeles, United StatesContact: Donald Kohn, MDTaking people

About the trial

What the trial wants to find out

This is a phase I/II open label multi-center study in which patients will receive low dose targeted busulfan followed by infusion of autologous CD34+ selected bone marrow or mobilized peripheral blood cells transduced with the G2SCID vector. Subjects will be enrolled over 3 years and be followed for 2 years post-infusion on this protocol, then followed long-term on a separate long-term follow-up protocol.

Read full original descriptionShow less

Enrollment of subjects will be agreed upon by representatives of both sites. Data will be collected uniformly from both sites through an electronic capture system and key laboratory studies will be centralized.

Harvest, cellular manufacturing and infusion will occur at each site using the same SOPs. Key aspects of cellular product characterization will be centralized

The group in the trial

  • Treatment armTreatment being tested

    single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) lentiviral vector G2SCID

    Treatment: autologous CD34+ cell transduced with G2SCID vector

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Criteria questions
Built from NCT03311503, who can take part
Record updated
11 December 2025